NicOx, TOPIGEN initiates phase 2 proof of concept study in COPD for TPI 1020

November 20, 2007 - ...This new clinical study follows the recent announcement of promising top-line results from a phase 2a study in asthmatic smokers, where TPI 1020 showed a good safety and tolerability profile, in addition to certain anti-inflammatory effects which could be potentially beneficial in COPD (see press release of September 11, 2007). COPD is a respiratory disease caused by chronic inflammation of the lungs and bronchi and represents the third-leading cause of death in the United States... [PDF] NicOx' Press Release - PDF en Français - [PDF] Topigen's Press Release -

TOPIGEN Pharmaceuticals, TPI 1020 Into Phase 2 Development for COPD

September 10, 2007 - TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in respiratory disorders, announced the successful completion of a Phase 2a safety trial with TPI 1020 in smokers with asthma.
TOPIGEN also announced plans to initiate a Phase 2 clinical trial of TPI 1020 in chronic obstructive pulmonary disease (COPD) in the second half of 2007.TPI 1020 is a novel anti-inflammatory respiratory drug licensed from NicOx S.A.

TOPIGEN Pharmaceuticals' Press Release -

NicOx's Press Release (PDF English) -

Communiqué de Presse NicOx en Français [PDF] -